HOOKIPA Pharma to Cut Workforce by 80%, Shift Focus to KRAS Cancer Program

MT Newswires Live11-21 20:42

HOOKIPA Pharma (HOOK) said late Wednesday that it would reduce its workforce by about 80% as part of its restructuring plan.

The company said it expects to begin the restructuring plan in Q4 and substantially complete it by the end of the first half of 2025.

As part of its restructuring plan, the company will pause clinical development of its eseba-vec program for HPV16-positive head and neck cancers, including the early termination of a phase 1/2 trial, despite no issues with efficacy or safety.

Additionally, Hookipa said it also prioritize its HB-700 program for KRAS mutant cancers, which received FDA clearance in April 2024.

The company will continue enrolling patients in its HB-500 HIV program and supporting its HB-400 Hepatitis B program, both developed in partnership with Gilead Sciences.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485498140?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485498140","market":"sg","top_or_hot":-1,"title":"HOOKIPA Pharma to Cut Workforce by 80%, Shift Focus to KRAS Cancer Program","media":"MT Newswires Live","content":"<html><body><p> HOOKIPA Pharma (HOOK) said late Wednesday that it would reduce its workforce by about 80% as part of its restructuring plan.</p><p>The company said it expects to begin the restructuring plan in Q4 and substantially complete it by the end of the first half of 2025.</p><p>As part of its restructuring plan, the company will pause clinical development of its eseba-vec program for HPV16-positive head and neck cancers, including the early termination of a phase 1/2 trial, despite no issues with efficacy or safety.</p><p>Additionally, Hookipa said it also prioritize its HB-700 program for KRAS mutant cancers, which received FDA clearance in April 2024.</p><p>The company will continue enrolling patients in its HB-500 HIV program and supporting its HB-400 Hepatitis B program, both developed in partnership with Gilead Sciences.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HOOKIPA Pharma to Cut Workforce by 80%, Shift Focus to KRAS Cancer Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHOOKIPA Pharma to Cut Workforce by 80%, Shift Focus to KRAS Cancer Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-21 20:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HOOKIPA Pharma (HOOK) said late Wednesday that it would reduce its workforce by about 80% as part of its restructuring plan.The company said it expects to begin the restructuring plan in Q4 and ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2485498140","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485498140","pubTimestamp":1732192977,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HOOKIPA Pharma (HOOK) said late Wednesday that it would reduce its workforce by about 80% as part of its restructuring plan.The company said it expects to begin the restructuring plan in Q4 and substa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HOOK":"Hookipa Pharma Inc","BK4505":"高瓴资本持仓"},"translate_title":"HOOKIPA Pharma将裁员80%，将重点转向KRAS癌症项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOOK":0.9},"content_text":"HOOKIPA Pharma (HOOK) said late Wednesday that it would reduce its workforce by about 80% as part of its restructuring plan.The company said it expects to begin the restructuring plan in Q4 and substantially complete it by the end of the first half of 2025.As part of its restructuring plan, the company will pause clinical development of its eseba-vec program for HPV16-positive head and neck cancers, including the early termination of a phase 1/2 trial, despite no issues with efficacy or safety.Additionally, Hookipa said it also prioritize its HB-700 program for KRAS mutant cancers, which received FDA clearance in April 2024.The company will continue enrolling patients in its HB-500 HIV program and supporting its HB-400 Hepatitis B program, both developed in partnership with Gilead Sciences.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485498140"}